Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Potential of Curcumin Extract as an Adjuvant Therapy in the Eradication of Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program (Program Makan Bergizi Gratis): Carrier Screening Followed by a Randomized, Double-Blind, Placebo-Controlled Trial

NCT07908030 is registered in ClinicalTrials.gov with Universitas Sebelas Maret as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07908030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
The Potential of Curcumin Extract as an Adjuvant Therapy in the Eradication of Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program (Program Makan Bergizi Gratis): Carrier Screening Followed by a Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Universitas Sebelas Maret
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 2, 2026
Completion date
October 22, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salmonella typhi infection, typhoid carrier, typhoid fever

Arms

As registered; 2 arms.

  • Ciprofloxacin + Curcumin Extract ExperimentalCiprofloxacin, Curcumin extract

    Culture-confirmed typhoid carriers take ciprofloxacin 500 mg by mouth twice daily plus curcumin extract 1,000 mg per day by mouth for 28 days.

  • Ciprofloxacin + Placebo Placebo comparatorCiprofloxacin, Placebo

    Culture-confirmed typhoid carriers take ciprofloxacin 500 mg by mouth twice daily plus placebo capsules (amylum) for 28 days. The placebo capsules look the same as the curcumin capsules.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of participants with negative Salmonella Typhi culture (eradication) 30 days after the end of the 28-day treatment

    A rectal swab is cultured on Salmonella Shigella Agar. Suspected colonies are confirmed with IMViC biochemical tests. Eradication means no growth of Salmonella Typhi. The proportion is compared between the two arms.

Lead sponsor's other trials

Universitas Sebelas Maret, most recent start first.

Similar trials

Same condition (Typhoid Fever) and phase, most recent start first.